Publication
Article
BioPharm International
Are Biopharma Patents Poised on the Post-Grant Chopping Block?
Author(s):
This article examines trends in biopharma post-grant patent review and projects what the future holds in store.
BioPharm International
eBooks Volume 28, Issue 14
Post-grant review of patents at the Patent Trial and Appeal Board (PTAB) has taken the intellectual property (IP) world by storm. Post-grant reviews allow anyone to challenge the validity of a patent far more quickly and cheaply than has ever before been possible. They have replaced the huge financial drain and business risk of traditional patent litigation with a rapid adjudication system that delivers certainty for a price comparable to a patent license fee. Read this article and other articles in
BioPharm International
's 2015
The Future of BioprocessingeBook.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
